GMAB Quote, Financials, Valuation and Earnings

Ascendis Pharma A/S has a net margin of 2.93% compared to Genmab A/S's net margin of -13.56%. Genmab A/S's return on equity of 17.69% beat Ascendis Pharma A/S's return on equity of -880.05%.

Genmab A/S has a consensus price target of $37.94, signalling upside risk potential of 29.55%. On the other hand Ascendis Pharma A/S has an analysts' consensus of $282.67 which suggests that it could grow by 25.48%. Given that Genmab A/S has higher upside potential than Ascendis Pharma A/S, analysts believe Genmab A/S is more attractive than Ascendis Pharma A/S.

Genmab A/S has a beta of 0.899, which suggesting that the stock is 10.054% less volatile than S&P 500. In comparison Ascendis Pharma A/S has a beta of 0.436, suggesting its less volatile than the S&P 500 by 56.356%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ascendis Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Ascendis Pharma A/S pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1.1B, which are larger than Ascendis Pharma A/S quarterly revenues of $288.1M. Genmab A/S's net income of $31M is higher than Ascendis Pharma A/S's net income of -$39.1M. Notably, Genmab A/S's price-to-earnings ratio is 18.92x while Ascendis Pharma A/S's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.00x versus 16.58x for Ascendis Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.

Krystal Biotech, Inc. has a net margin of 2.93% compared to Genmab A/S's net margin of 47.99%. Genmab A/S's return on equity of 17.69% beat Krystal Biotech, Inc.'s return on equity of 19.22%.

Genmab A/S has a consensus price target of $37.94, signalling upside risk potential of 29.55%. On the other hand Krystal Biotech, Inc. has an analysts' consensus of $306.56 which suggests that it could grow by 17.1%. Given that Genmab A/S has higher upside potential than Krystal Biotech, Inc., analysts believe Genmab A/S is more attractive than Krystal Biotech, Inc..

Genmab A/S has a beta of 0.899, which suggesting that the stock is 10.054% less volatile than S&P 500. In comparison Krystal Biotech, Inc. has a beta of 0.493, suggesting its less volatile than the S&P 500 by 50.719%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Krystal Biotech, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Krystal Biotech, Inc. pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1.1B, which are larger than Krystal Biotech, Inc. quarterly revenues of $107.1M. Genmab A/S's net income of $31M is lower than Krystal Biotech, Inc.'s net income of $51.4M. Notably, Genmab A/S's price-to-earnings ratio is 18.92x while Krystal Biotech, Inc.'s PE ratio is 38.25x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.00x versus 20.13x for Krystal Biotech, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novo Nordisk A/S has a net margin of 2.93% compared to Genmab A/S's net margin of 33.98%. Genmab A/S's return on equity of 17.69% beat Novo Nordisk A/S's return on equity of 62.44%.

Genmab A/S has a consensus price target of $37.94, signalling upside risk potential of 29.55%. On the other hand Novo Nordisk A/S has an analysts' consensus of $53.78 which suggests that it could grow by 13.4%. Given that Genmab A/S has higher upside potential than Novo Nordisk A/S, analysts believe Genmab A/S is more attractive than Novo Nordisk A/S.

Genmab A/S has a beta of 0.899, which suggesting that the stock is 10.054% less volatile than S&P 500. In comparison Novo Nordisk A/S has a beta of 0.667, suggesting its less volatile than the S&P 500 by 33.292%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novo Nordisk A/S offers a yield of 3.64% to investors and pays a quarterly dividend of $0.58 per share. Genmab A/S pays -- of its earnings as a dividend. Novo Nordisk A/S pays out 38.07% of its earnings as a dividend. Novo Nordisk A/S's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Genmab A/S quarterly revenues are $1.1B, which are smaller than Novo Nordisk A/S quarterly revenues of $12.3B. Genmab A/S's net income of $31M is lower than Novo Nordisk A/S's net income of $4.2B. Notably, Genmab A/S's price-to-earnings ratio is 18.92x while Novo Nordisk A/S's PE ratio is 13.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.00x versus 4.52x for Novo Nordisk A/S. Usually stocks with elevated PS ratios are considered overvalued.

Zealand Pharma A/S has a net margin of 2.93% compared to Genmab A/S's net margin of -550.12%. Genmab A/S's return on equity of 17.69% beat Zealand Pharma A/S's return on equity of 51.22%.

Genmab A/S has a consensus price target of $37.94, signalling upside risk potential of 29.55%. On the other hand Zealand Pharma A/S has an analysts' consensus of -- which suggests that it could fall by -62.76%. Given that Genmab A/S has higher upside potential than Zealand Pharma A/S, analysts believe Genmab A/S is more attractive than Zealand Pharma A/S.

Genmab A/S has a beta of 0.899, which suggesting that the stock is 10.054% less volatile than S&P 500. In comparison Zealand Pharma A/S has a beta of 0.725, suggesting its less volatile than the S&P 500 by 27.461%.

Genmab A/S has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zealand Pharma A/S offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Genmab A/S pays -- of its earnings as a dividend. Zealand Pharma A/S pays out -- of its earnings as a dividend.

Genmab A/S quarterly revenues are $1.1B, which are larger than Zealand Pharma A/S quarterly revenues of $10.7M. Genmab A/S's net income of $31M is higher than Zealand Pharma A/S's net income of -$59.1M. Notably, Genmab A/S's price-to-earnings ratio is 18.92x while Zealand Pharma A/S's PE ratio is 4.43x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Genmab A/S is 5.00x versus 3.06x for Zealand Pharma A/S. Usually stocks with elevated PS ratios are considered overvalued.